Pipeline / 01 · Platforms

Immune Cell Banking Platform

Pre-engineered, AI-preconditioned immune cell reserves — a living biological insurance for every client.

WIDE-SCALE MOVACCINE™ DEPLOYMENT From collection to cure, in seven to fourteen days. PATIENT 01 MOScan™ Provision of starting material 02 Cell Selection & Activation 03 MOMap™ Genetic Modification 04 Cell Expansion Proliferation in bioreactor 05 MOStore™ Cryopreservation / Formulation 06 MOVaccine™ Injection Echo C-One™ AI orchestrates each transition with continuous real-time clinical feedback.
The MOVaccine™ deployment cycle — from MOScan™ starting material provision, through MOMap™ genetic modification, cell expansion, MOStore™ cryopreservation, and injection. Delivers engineered cell therapy within 7–14 days from cryo to infusion.
Premise

The problem we are solving.

Traditional stem cell banks store raw cells passively, then hope they still work decades later. MACRO HRD goes beyond stem cells: we collect, isolate, pre-engineer, and cryopreserve a client's full immune portfolio — T cells, NK cells, B cells, MSCs, dendritic cells — each pre-conditioned against that individual's genomic and proteomic baseline.

The result is not a biological time capsule but an engineering-ready therapeutic reserve. When illness arrives, cells are retrieved, AI-guided re-engineered using MOMap™, and deployed as personalized CAR-T, CAR-γδ, or MSC therapies within 7–14 days from cryo to infusion.

Approach

How we tackle it.

The Immune Cell Banking platform is powered by a family of proprietary systems that together define the full lifecycle — MOMap™ (genomic-AI platform mapping patient HLA, mutation, and epitope data), MOScan™ (real-time variant detection and therapy activation signals), MOStore™ (GMP- and ISO-compliant cryogenic infrastructure with sovereign legal protections), MOVaccine™ (personalized autologous T cell vaccine pipeline), CryoVault™ (integrated redundant LN₂ storage with decades-long viability guarantees), and Echo C-One™ (the central AI engine linking genomic data to banked cells).

Every step is AI-guided. Pre-conditioning cocktails are tailored to the donor's genotype. Harvest windows are optimized by stress-biomarker trajectories. QC is continuous rather than end-point. The bank does not wait passively — it actively primes cells for eventual therapeutic use.

CLINICAL WORKFLOW COMPARISON Standard banks store. We prepare. STEP 1 Sample / Source Standard: peripheral blood MACRO HRD: high-yield leukapheresis STEP 2 Cell Isolation Standard: PBMCs only MACRO HRD: full T/B/NK/γδ panel STEP 3 Cell Processing Standard: minimal MACRO HRD: cytokine-primed activation STEP 4 Cell Cultivation Standard: not performed MACRO HRD: clinical-scale expansion STEP 5 Cryopreservation Standard: DMSO freeze MACRO HRD: controlled-rate, 80–90% post-thaw STEP 6 Banking Standard: untracked MACRO HRD: 21 CFR Part 11 compliant
Clinical workflow comparison — standard biobank approach versus MACRO HRD's 6-step engineered workflow. Standard banks store raw cells passively; MACRO HRD actively primes cells for functional use through each of six protocol-controlled stages.
i.
Source collection
Peripheral blood or high-yield leukapheresis during healthy periods to preserve future therapeutic options.
ii.
Cell isolation
Automated cell selection for T, B, NK, γδ T subsets using CliniMACS Prodigy with full traceability.
iii.
Pre-conditioning
Cytokine cocktails (IL-7, IL-15) and epigenetic conditioning guided by donor's genomic profile.
iv.
Cryopreservation
Controlled-rate freezing with CryoStor or HSA protocols — 80–90% post-thaw viability.
v.
Echo C-One integration
Banked cells linked to continuously updated clinical data for activation-readiness monitoring.
vi.
On-demand retrieval
Cells retrieved, engineered, and deployed as personalized CAR-T or γδ T therapy within 7–14 days.
INTEGRATED PLATFORM FLOW · GENE TO CURE Powered by Echo C-One™ AI Engine. Baseline Data & Cell Collection MOMAP™ · MOSCAN™ Genomic and clinical data Proactive Bio-Banking MOSTORE™ Patient cells cryopreserved On-Demand AI-Driven Engineering MOVACCINE™ · CAR-ΓΔ Cells retrieved and engineered Treatment & Ex Vivo Monitoring PATIENTTREATMENT Therapy administered and monitored ⸻ Continuous clinical feedback loop ⸻
The Echo C-One™ AI engine links baseline data collection, proactive bio-banking, on-demand engineering, and treatment monitoring into a closed clinical feedback loop — powered continuously by patient-specific data.
Capabilities

What makes this real.

01
Beyond stem cell banking
Complete immune portfolio preserved — T, NK, B, MSC, dendritic cells — not just hematopoietic stem cells.
02
Pre-engineered readiness
Cells arrive at storage already primed for therapeutic use, not frozen in raw form awaiting later engineering.
03
Sovereign data governance
PDPA/GDPR/HIPAA-compliant infrastructure with blockchain-audited consent and jurisdiction-specific data residency.
04
AI-matched activation
Echo C-One™ continuously matches banked cells against emerging clinical data, flagging re-activation opportunities.
BEYOND STEM CELLS · FULL-SPECTRUM PORTFOLIO A complete immune portfolio, not just stem cells. CELL TYPE SUBSETS APPLICATIONS DIFFERENTIATION T cells CD4⁺ helper, CD8⁺, γδ T CAR-T therapies, vaccines, viral immunotherapy Effector cells preserved engineering-ready NK cells Peripheral NK subsets CAR-NK therapies, antiviral, anti-tumor First-in-class — rarely banked elsewhere B cells Memory and naïve B cells Antibody libraries, autoimmune therapy Personalized antibody factory at scale MSC Bone marrow, adipose, cord Tissue regeneration, anti-inflammatory AI-guided priming protocols DCs Myeloid DCs, monocytes DC vaccines, T cell priming, antiviral training First systematic preservation for vaccine use
Beyond stem cells — full-spectrum immune cell banking. Preserves T cells, NK cells, B cells, MSCs, and dendritic cells with AI-driven pre-conditioning tailored to each client's genomic profile.
Where It Connects

Part of an integrated platform.

01 · Platforms
GEDM-3DQ Decision Engine
Gradient Equilibrium Decision Modeling in 3-Dimensional Quadrant — the AI spine of every MACRO HRD program.
01 · Platforms
Engineered Immune Cells Platform
CAR-like NK systems and γδ T cell therapies for adaptive, MHC-independent elimination of diseased cells.
04 · Infrastructure
Ambient Cell Logistics
Room-temperature cell logistics — a bioinspired sporulation strategy that ends cold-chain dependency for cellular therapies.
02 · Infectious Disease
HIV Functional Cure Program
An integrated therapeutic approach combining tri-specific antibodies, CAR-like NK effectors, AH-D peptide activation, and GEDM-3DQ-guided coordination.
⸻ Continue the platform

“We do not store cells as memory. We store them as preparation.”

See all ventures → Engage with MACRO HRD